The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $119.52

Today's change+1.30 +1.10%
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $119.52

Today's change+1.30 +1.10%
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.

Celgene Corp up (U.S.)$1.30

Celgene Corp closed up Thursday by (U.S.)$1.30 or 1.10% to (U.S.)$119.52. Over the last five days, shares have gained 0.60% and 6.85% year to date. Shares have outperformed the S&P 500 by 28.10% during the last year.

Key company metrics

  • Open(U.S.) $118.56
  • Previous close(U.S.) $118.22
  • High(U.S.) $119.89
  • Low(U.S.) $118.52
  • Bid / Ask-- / --
  • YTD % change+6.85%
  • Volume4,288,088
  • Average volume (10-day)4,361,434
  • Average volume (1-month)4,176,351
  • Average volume (3-month)4,598,935
  • 52-week range(U.S.) $82.90 to (U.S.) $129.06
  • Beta0.99
  • Trailing P/E40.83×
  • P/E 1 year forward25.22×
  • Forward PEG1.00×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.93
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+30.41%

Based on its net profit margin of 30.41%, Celgene Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.30%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue2,0812,0861,9821,873
Total other revenue--------
Total revenue2,0812,0861,9821,873
Gross profit1,9771,9821,8851,774
Total cost of revenue1041039899
Total operating expense1,2241,3341,3381,116
Selling / general / administrative529544498492
Research & development506585675457
Depreciation / amortization64646465
Interest expense (income), net operating--------
Unusual expense (income)213843
Other operating expenses, total--------
Operating income857752645757
Interest income (expense), net non-operating-63-64-64-52
Gain (loss) on sale of assets--------
Other--------
Income before tax827711578707
Income after tax719614509598
Income tax, total1089769109
Net income719614509598
Total adjustments to net income--------
Net income before extra. items719614509598
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items719614509598
Inc. avail. to common incl. extra. items719614509598
Diluted net income719614509598
Dilution adjustment--------
Diluted weighted average shares834835833831
Diluted EPS excluding extraordinary itemsvalue per share0.860.740.610.72
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.880.770.610.72